| |
| |
|
|
All News
Aug 6, 2008
MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
San Diego, CA -- MabVax Therapeutics Inc., a privately held immunotherapeutics discovery and development company focused on the development and commercialization of novel immunotherapies for the treatment of cancer, today announced the completion of two separate licensing agreements with the Memorial Sloan-Kettering Cancer Center’s Sloan-Kettering Institute for Cancer Research (SKI). Read More...
Feb 27, 2008
MabVax Therapeutics Closes $8 Million Series A Financing with GBP Capital
Greenwich, CT and San Diego, CA -- MabVax Therapeutics Inc., a privately held immunotherapeutics discovery and development company focused on the development and commercialization of novel immunotherapies for the treatment of cancer, today announced the completion of a eight million dollar venture financing with GBP Capital. Read More...
|
|
|
|
